amycretin - Search News

Novo Nordisk, amycretin

Hosted on MSN · 1d

Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.

YAHOO!Finance · 1d

Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,

Novo Nordisk’s next-generation obesity treatment shows promise in early study

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.

BioPharma Dive1d

Novo shares climb on early data for dual-acting obesity drug

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

1d

Novo Nordisk amycretin data helps rebut concerns, says BofA

After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results